India Pharmaceuticals & Healthcare Report Q3 2014 - New Study Released

The Pharmaceutical Research and Manufacturers of America (PhRMA)'s decision to list India as a Priority Foreign Country illustrates pharmaceutical companies' escalating dis contentment with the country due to a series of patent disrespect issues. We maintain that low government spending on healthcare is the root of the problem, as it limits patients' access to services . However, we do not expect the situation to improve in the near term, and the affordability of patented pharmaceuticals will remain an issue between the US and India.

Headline Expenditure Projections

Pharmaceuticals: INR904.0bn (USD15.4bn) in 2013 to INR1,000.6bn (USD17.3bn) in 2014; +10.7% in local currency terms and +11.8% in US dollar terms. Forecast broadly in line with previous quarter.

Full Report Details at
- http://www.fastmr.com/prod/837687_india_pharmaceuticals_healthcare_report_q3_2014.aspx?afid=301

Healthcare: INR4,523.5bn (USD77.2bn) in 2013 to INR5,043.1bn (USD87.0bn) in 2014; +11.5% in local currency terms and 12.6% in US dollar terms. Forecast upgraded due to receipt of historic data from the World Health Organization.

Risk/Reward Rating

India's Pharmaceutical Risk/Reward Rating (RRR) score for Q314 is 53.0 out of the maximum 100, in our newly improved RRR system. The country scored above average for some indicators and sub-indicators including overall market expenditure, sector value growth, population growth. Nevertheless, it scored below regional average for most indicators under industry and country risks. Consequently with the moderate score, India is ranked tenth, behind New Zealand, out of the 19 key markets in Asia Pacific.

Key Trends And Developments

* In May 2014, the Indian government announced it will spend more than INR30bn (USD510mn) over the next three years to increase pharmaceutical regulatory capacity at the federal and state level. The number of regulatory inspectors at the Central Drugs Standard Control Organization (CDSCO) will double to 1,000, while the number of officials at state regulatory departments will increase from 800 to 3,000. D.N. Singh, Drug...

The India Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's India Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Indian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for India to test other views - a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2014
- Peru Pharmaceuticals & Healthcare Report Q3 2014
- France Pharmaceuticals & Healthcare Report Q3 2014
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014